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Intramacrophagic Anti-infectious therapies
Nanotechnology is a fascinating world that has provided and still
provides sensational developments in many fields such as in
pharmaceutics for diagnosis or drug and gene delivery to cells, tissues
or organs. With regard to the latter, cell uptake of nanostructures
(generally 1-100 nm) is usually much greater than that of
microparticles in the range of 1-10 µm. Although the term “nano”
remains of high impact, not always the nanosize is preferable to a
larger size. One of these cases is represented by the inhalation of drugs
transported within particulate carrier in order to reach the Alveolar
Macrophages (AM) and eradicate surviving intracellular bacteria in
pathologies such as tuberculosis, HIV, S. pneumoniae and S. aureus
infections.
For an Intramacrophagic anti-infectious therapy by pulmonary
administration, most antibiotics are poorly soluble in water and their
aerosolization has to be produced by using drugs in their solid state
administered by means of Dry Powder Inhaler (DPI) devices. In this
regard, it is rare that untreated drugs have features suitable for both
DPI performance and targeting to AM failing to both reach alveolar
epithelium and penetrate AM effectively. Therefore, particle
engineering techniques have been proposed for both drug alone
(micronization, polymorphic transformations, controlled
crystallization, intermolecular self-assembling, spray-drying producing
irregular shaped particles) and drug/excipient blending (with lactose
or mannitol) or carrier-based formulations (liposomes, polymeric/lipid
microparticles, cyclodextrins).
Various inhaled particulate carriers containing therapeutic agents
have been used to deliver drugs to the AM leading to intracellular
concentrations of the antibiotic up to 20-fold enriched compared to the
administration of free drug [1]. Particulate systems have also been
engineered to facilitate uptake by macrophages or surface modified for
receptor-mediated AM endocytosis [2].
Regarding particulate carrier-based formulations, among several
other properties, particle size is crucial not only to guarantee effective
dose emission by DPI, powder dispersion and deposition onto alveolar
epithelium, but also effective endocytosis by AM that correlates with
the efficacy of the loaded antimicrobial agents, i.e., the adequate local
antibacterial concentration (>> MIC). The literature review shows
several nanoparticle platforms for AM intracellular therapy.
Nevertheless, particle deposition onto the distal respiratory tract
(breathability) is a prerogative of microsize particles in the
aerodynamic size from 0.5 to 5 µm (but also 0.5-3, 0.5-2, or 3-6 µm
ranges are referred) while particles smaller than 0.5 μm are mostly
exhaled without deposition [3]. Contrary to this, particles larger than 2
or 5 μm, according to the data reported by the researchers, have a
lower possibility of bypassing the upper airways. From the perspective
of the AM endocytosis, the literature shows a wide view of dimensional
conditions under which AM uptake would be subjected according to
the size dictating endocytosis mechanism: phagocytosis (particularly
1-3 µm), macropinocytosis (0.2-10 µm), or pinocytosis (<0.2 µm).
It is essential to underline that cell-particle interactions are
modulated also by other physico-chemical properties as well as cell-
specific parameters such as macrophage type, i.e. the tissues where
macrophage reside. For instance, some authors refer optimal sizes of
the particles for the phagocytic uptake by AM in the range between 3
μm and 6 μm, but those by peritoneal macrophages and peripheral
blood mononuclear cells from 0.3 μm to 1.1 μm [1].
However, the impact of particle size on both passive and active
uptake is considered a key parameter with a tendency to assume and
demonstrate that nanoparticles largely escape uptake by AM. Indeed,
although endocytic mechanisms can involve nanoparticles, the actual
amounts taken up should be assayed before a possible consideration.
For example, 0.1% of the inhaled dose by macrophages within 24 h was
found for inhaled 20 nm titanium dioxide particles. For comparison,
macrophages uptake of 3 to 6 μm particles was two orders of
magnitude larger [4]. Contrary to this, microparticles of 1-3 μm in
diameter are far better and extensively taken up by AM and those of
1 μm-10 μm diameters are regarded to be the most favourable.
Thus, it seems reasonable sharing the opinion that the
microparticles would be more effective than nanoparticles for the
pulmonary treatment of intramacrophagic bacteria, especially in terms
of breathability. For this reason, new technological approaches have led
to the development of hybrid vectors in which nanoparticles are
embedded in microparticulate shells so improving the aerodynamic
properties of the native nanoparticles and, at the same time, reducing
the possible nanoparticle harmful effects [5-7].
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